At a point when Novavax (NVAX) investors expected the small biotech to commence sales on Resolve, the company is restarting Phase 2 trials again. About 3 months after reporting failed Phase 3 trials, Novavax is starting a test for the RSV F vaccine in older adults. The clinical trials will assess safety and immunogenicity of the vaccine in 300 older adults (60+) in the Southern Hemisphere with toppling results by Q3. The Phase 3 trial for infants via maternal immunization is progressing though the size of that market is immaterial compared to the older adults vaccine. The targeted infant population in the U.S. is only 4 million while the older adult population is approximately 65 million and growing. The company expects the Phase 3 results possibly by year end.Ultimately, a positive result for Prepare would provide the market with confidence in management. The real question remains the cash position. When the company reports Q4 numbers at the end of February, the market will focus close on the cash burn and the guidance for updated expenses as the Phase 2 Resolve trails ramp up. The stock remains in the avoid section until the cash situation is resolved. Anybody trading the stock?Disclosure: No position